CHRİS GİORDANO, CHRİS JOHNSON, JANİCE LAWSON, ANİTA RAJASEKHAR, ELİZABETH THOMAS
Experimental and Clinical Transplantation - 2021;19(3):269-272
Liver transplant has occasionally been performed in the presence of congenital afibrinogenemia and has been rarely used to treat it. Historically, to safely manage coagulopathy during transplant, these patients have been administered a combination of fresh frozen plasma and cryoprecipitate. In this case report, we discuss the first reported use of recombinant fibrinogen to treat such a patient and the decision-making process considered to balance the thrombotic and hemorrhagic risks.
